Recent progress and concerns regarding the Japanese immunization program: Addressing the "vaccine gap"

Vaccine

Volumn 32, Issue 34, 2014, Pages 4253-4258

  Saitoh, Akihiko ^a,b   Okabe, Nobuhiko ^c  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAWASAKI CITY INSTITUTE FOR PUBLIC HEALTH   (Japan)

Author keywords

Congenital rubella syndrome; Conversion disorder; Human papilloma virus vaccine; Immunization program; Japan; Rubella; Vaccine gap

Indexed keywords

RUBELLA VACCINE; WART VIRUS VACCINE;

BCG VACCINATION; BUDGET; CHRONIC PAIN; DEVELOPED COUNTRY; DRUG WITHDRAWAL; EPIDEMIC; HUMAN; IMMUNIZATION; JAPAN; LAW; PRIORITY JOURNAL; REVIEW; RUBELLA; CHEMICALLY INDUCED; DRUG RECALL; HEALTH CARE POLICY; LEGISLATION AND JURISPRUDENCE; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE;

CHRONIC PAIN; EPIDEMICS; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; JAPAN; PAPILLOMAVIRUS VACCINES; RUBELLA; SAFETY-BASED DRUG WITHDRAWALS;

EID: 84903820581     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.022     Document Type: Review

References (28)

1. Saitoh A., Okabe N. Current issues with the immunization program in Japan: can we fill the "vaccine gap"?. Vaccine 2012, 30:4752-4756.
2. Centers for Disease Control and Prevention Nationwide rubella epidemic-Japan, 2013. MMWR Morb Mortal Wkly Rep 2013, 62:457-462.
3. Minakami H., Kubo T., Unno N. Causes of a nationwide rubella outbreak in Japan, 2012-2013. J Infect 2014, 68:99-101.
4. Ihara T.S.S., Asada K., et al. Effectiveness of introduction of Haemophilus influenzae type b vaccine and 7-valent conjugate pneumococcal vaccines on invasive bacterial diseases. Infect Agents Surveill Rep 2012, 33:71-72.
5. Japan Pediatric Society, Immunization schedule recommended by Japan Pediatric Society, (accessed on 5/15/2014). http://www.jpeds.or.jp/uploads/files/JPS%20Vaccine%20Schedule%20English%2020140317.pdf.
6. Diekema D.S. Improving childhood vaccination rates. N Engl J Med 2012, 366:391-393.
7. Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974, 2:1288-1290.
8. Yamamoto S., Yamamoto T. Historical review of BCG vaccine in Japan. Jpn J Infect Dis 2007, 60:331-336.
9. WHO Global tuberculosis report 2013 2013, WHO.
10. Norouzi S., Aghamohammadi A., Mamishi S., Rosenzweig S.D., Rezaei N. Bacillus Calmette-Guerin (BCG) complications associated with primary immunodeficiency diseases. J Infect 2012, 64:543-554.
11. Kamiya H., Okabe N. Leadership in immunization: the relevance to Japan of the U.S.A. experience of the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP). Vaccine 2009, 27:1724-1728.
12. Ueda K., Miyazaki C., Hidaka Y., Okada K., Kusuhara K., Kadoya R. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet 1995, 346:701-702.
13. Centers for Disease Control and Prevention Progress toward measles elimination-Japan, 1999-2008. MMWR Morb Mortal Wkly Rep 2008, 57:1049-1052.
14. Gherardi R.K., Coquet M., Cherin P., Authier F.J., Laforet P., Belec L., et al. Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet 1998, 352:347-352.
15. Beerthuizen A., van't Spijker A., Huygen F.J., Klein J., de Wit R. Is there an association between psychological factors and the Complex Regional Pain Syndrome type 1 (CRPS1) in adults? A systematic review. Pain 2009, 145:52-59.
16. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012, 30(Suppl 5):F139-F148.
17. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302:750-757.
18. Gold M.S., McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sex Health 2010, 7:320-324.
19. Arnheim-Dahlstrom L., Pasternak B., Svanstrom H., Sparen P., Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013, 347:f5906.
20. WHO, WHO recommendations for routine immunization, (accessed on 5/15/2014). http://wwwwhoint/immunization/policy/immunization_tables/en/indexhtml.
21. Sadzot-Delvaux C., Rentier B., Wutzler P., Asano Y., Suga S., Yoshikawa T., et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis 2008, 197(Suppl 2):S185-S190.
22. Ozaki T. Varicella vaccination in Japan: necessity of implementing a routine vaccination program. J Infect Chemother 2013, 19:188-195.
23. Katsuta T., Kato H., Kaneko Y., Kaneko M., Misaki Y., Kimura M., et al. Complete atrioventricular block as a complication of varicella in children. Pediatr Infect Dis J 2011, 30:445-446.
24. Yoshida M., Hayasaka S., Yamada T., Yanagisawa S., Hayasaka Y., Nakamura N., et al. Ocular findings in Japanese patients with varicella-zoster virus infection. Ophthalmologica 2005. 219:272-275. Journal international d'ophtalmologie International journal of ophthalmology Zeitschrift fur Augenheilkunde.
25. Shinjoh M., Takahashi T. Varicella zoster exposure on paediatric wards between 2000 and 2007: safe and effective post-exposure prophylaxis with oral aciclovir. J Hosp Infect 2009, 72:163-168.
26. Gustafson T.L., Lavely G.B., Brawner E.R., Hutcheson R.H., Wright P.F., Schaffner W. Anoutbreak of airborne nosocomial varicella. Pediatrics 1982, 70:550-556.
27. Hashimoto H, Fujioka M, Kinumaki H. An office-based prospective study ofdeafness in mumps. Pediatr Infect Dis J 2009;28:173-5.
28. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)